Shanghai Jiading is rapidly advancing the development of a high-end medical device industry cluster, aiming to establish itself as an influential and competitive hub for biopharmaceutical innovation in the Yangtze River Delta region.

At the 2025 Jiading Biopharmaceutical Industry Development Conference and China High-End Medical Industry Cluster Innovation Cooperation Forum held on November 26, it was revealed that Shanghai has introduced an action plan to promote the full-chain development of the high-end medical device sector. The plan emphasizes accelerating the construction of industrial clusters, supporting innovative enterprises in scaling up, and facilitating the global expansion of locally developed medical devices.

As one of Shanghai’s three major high-end medical device clusters, Jiading is intensifying efforts to pool resources and drive innovation in the industry. The district boasts top-tier innovation assets, including Ruijin Hospital’s National Medical Center and Fudan University’s International Science and Technology Innovation Center, as well as industry leaders such as United Imaging Healthcare.

Two key projects—"Shanghai Med Valley" and "United Imaging Town"—are under development, with the former focusing on medical devices and the latter on high-end medical equipment, creating a complementary and synergistic ecosystem.

According to the plan, by 2027, Jiading aims to become a globally competitive high-end medical device cluster, with progress measured across three dimensions:

1. **Innovation**: Achieve "dual growth" by securing over 100 domestic Class III medical device approvals and more than 30 overseas market authorizations. Establish 2–3 high-quality innovation platforms, such as technology centers, concept validation hubs, and specialized incubators.

2. **Enterprise Development**: Cultivate a "dual-tiered" enterprise ecosystem, nurturing one globally competitive leader, 2–3 niche champions, and a cohort of specialized "little giant" and unicorn firms with core technologies.

3. **Industrial Scale**: Realize "dual breakthroughs" by reaching RMB 25 billion in high-end medical device manufacturing output and RMB 50 billion in total industry scale by 2027, reflecting the maturity of the cluster’s ecosystem.

During the conference, several high-level research institutions specializing in cardiovascular, neurological, and endocrine fields announced their relocation to Shanghai Med Valley. Ruijin Hospital and Mindray Medical also unveiled a joint innovation and transformation platform to deepen integration between clinical resources and industrial innovation.

Five cutting-edge medical-engineering crossover achievements were showcased, including a flexible endoscopic robot, bendable ultrasonic scalpel, photon-counting spectral CT, cloud-based imaging systems, and sequencers, highlighting Jiading’s innovation capabilities.

To foster an open and collaborative industrial ecosystem, five synergistic innovation scenarios were introduced, covering the entire value chain from R&D to commercialization. These include: - **Xinnuo Medical Device Validation and Clinical Skills Training Platform** - **United Imaging’s Global Healthcare Internet Platform** - **Shanghai Pharmaceutical Modern Medical Device Innovation Platform** - **Winner Medical Health Collaborative Innovation Platform** - **Shanghai (Nanxiang) International Precision Medicine Innovation Center**

These initiatives are expected to enhance government-enterprise coordination and functional integration, further solidifying Jiading’s position as a leader in high-end medical device innovation.